Mark J. Salji

Cancer Research UK Scotland Institute — United Kingdom

Medicine · Health Sciences

14h-index923citations71works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(47), Cancer, Lipids, and Metabolism(18), Prostate Cancer Diagnosis and Treatment(13), PARP inhibition in cancer therapy(13), Receptor Mechanisms and Signaling(11)

Publications71 total

A contemporary analysis of disease upstaging of Gleason 3 + 3 prostate cancer patients after robot‐assisted laparoscopic prostatectomy
Cancer Medicine·2023· 2 citedOpen Access
A contemporary analysis of disease upstaging of gleason 3+3 prostate cancer patients after Robot-Assisted Laparoscopic Prostatectomy (RALP)
European Urology Open Science·2023Open Access
Data from SLFN5 Regulates LAT1-Mediated mTOR Activation in Castration-Resistant Prostate Cancer
2023Open Access
Supplementary Information from SLFN5 Regulates LAT1-Mediated mTOR Activation in Castration-Resistant Prostate Cancer
2023Open Access
Supplementary Data 3 from SLFN5 Regulates LAT1-Mediated mTOR Activation in Castration-Resistant Prostate Cancer
2023Open Access
Supplementary Data 5 from SLFN5 Regulates LAT1-Mediated mTOR Activation in Castration-Resistant Prostate Cancer
2023Open Access
Supplementary Data 7 from SLFN5 Regulates LAT1-Mediated mTOR Activation in Castration-Resistant Prostate Cancer
2023Open Access
Supplementary Data 2 from SLFN5 Regulates LAT1-Mediated mTOR Activation in Castration-Resistant Prostate Cancer
2023Open Access
Supplementary Data 2 from SLFN5 Regulates LAT1-Mediated mTOR Activation in Castration-Resistant Prostate Cancer
2023Open Access
Supplementary Data 6 from SLFN5 Regulates LAT1-Mediated mTOR Activation in Castration-Resistant Prostate Cancer
2023Open Access
Supplementary Data 1 from SLFN5 Regulates LAT1-Mediated mTOR Activation in Castration-Resistant Prostate Cancer
2023Open Access
Supplementary Data 6 from SLFN5 Regulates LAT1-Mediated mTOR Activation in Castration-Resistant Prostate Cancer
2023Open Access
Supplementary Data 3 from SLFN5 Regulates LAT1-Mediated mTOR Activation in Castration-Resistant Prostate Cancer
2023Open Access
Table S1 from SLFN5 Regulates LAT1-Mediated mTOR Activation in Castration-Resistant Prostate Cancer
2023Open Access
Supplementary Data 5 from SLFN5 Regulates LAT1-Mediated mTOR Activation in Castration-Resistant Prostate Cancer
2023Open Access
Supplementary Data 1 from SLFN5 Regulates LAT1-Mediated mTOR Activation in Castration-Resistant Prostate Cancer
2023Open Access
Supplementary Information from SLFN5 Regulates LAT1-Mediated mTOR Activation in Castration-Resistant Prostate Cancer
2023Open Access
Supplementary Data 4 from SLFN5 Regulates LAT1-Mediated mTOR Activation in Castration-Resistant Prostate Cancer
2023Open Access
Supplementary Data 4 from SLFN5 Regulates LAT1-Mediated mTOR Activation in Castration-Resistant Prostate Cancer
2023Open Access
Supplementary Data 7 from SLFN5 Regulates LAT1-Mediated mTOR Activation in Castration-Resistant Prostate Cancer
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Hing Y. Leung(36), Arnaud Blomme(18), Chara Ntala(18), Colin Nixon(18), Sérgio Lilla(18), Sara Zanivan(18), David Sumpton(17), Gillian Mackay(16), Giovanny Rodriguez Blanco(15), Linda Rushworth(15), Laura C.A. Galbraith(14), Ann Hedley(14), Sonia H.Y. Kung(14), Martin Gleave(14), Paul Peixoto(13), Éric Hervouet(13), Ladan Fazli(13), Rafael S. Martinez(13), Elodie Renaude(12), Luke Gaughan(11)